NASDAQ:IPA ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis $0.56 +0.02 (+4.31%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ImmunoPrecise Antibodies Stock (NASDAQ:IPA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IPA alerts:Sign Up Key Stats Today's Range$0.54▼$0.5650-Day Range$0.34▼$0.5652-Week Range$0.27▼$1.18Volume167,720 shsAverage Volume2.11 million shsMarket Capitalization$25.45 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Read More… ImmunoPrecise Antibodies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreIPA MarketRank™: ImmunoPrecise Antibodies scored higher than 57% of companies evaluated by MarketBeat, and ranked 453rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoPrecise Antibodies has only been the subject of 2 research reports in the past 90 days.Read more about ImmunoPrecise Antibodies' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.27) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoPrecise Antibodies is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoPrecise Antibodies is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoPrecise Antibodies has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ImmunoPrecise Antibodies' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.42% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently decreased by 72.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunoPrecise Antibodies does not currently pay a dividend.Dividend GrowthImmunoPrecise Antibodies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.42% of the float of ImmunoPrecise Antibodies has been sold short.Short Interest Ratio / Days to CoverImmunoPrecise Antibodies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ImmunoPrecise Antibodies has recently decreased by 72.61%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.31 News SentimentImmunoPrecise Antibodies has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for ImmunoPrecise Antibodies this week, compared to 1 article on an average week.MarketBeat Follows2 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.Percentage Held by InstitutionsOnly 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.Read more about ImmunoPrecise Antibodies' insider trading history. Receive IPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoPrecise Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address IPA Stock News HeadlinesImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Upgraded by Wall Street ZenMay 26 at 1:39 AM | americanbankingnews.comImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement EffortsMay 21, 2025 | businesswire.comJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 28, 2025 | Premier Gold Co (Ad)ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech ConferenceMay 20, 2025 | businesswire.comIPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | finance.yahoo.comIPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | businesswire.comSee More Headlines IPA Stock Analysis - Frequently Asked Questions How have IPA shares performed this year? ImmunoPrecise Antibodies' stock was trading at $0.4117 at the start of the year. Since then, IPA shares have increased by 34.8% and is now trading at $0.5550. View the best growth stocks for 2025 here. How were ImmunoPrecise Antibodies' earnings last quarter? ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its quarterly earnings results on Friday, March, 28th. The company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The business had revenue of $4.23 million for the quarter, compared to analyst estimates of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative trailing twelve-month return on equity of 73.74%. Read the conference call transcript. Who are ImmunoPrecise Antibodies' major shareholders? ImmunoPrecise Antibodies' top institutional investors include Simplex Trading LLC. How do I buy shares of ImmunoPrecise Antibodies? Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ImmunoPrecise Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Last Earnings3/28/2025Today5/28/2025Next Earnings (Estimated)8/04/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IPA CIK1715925 Webwww.immunoprecise.com Phone250-483-0308FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$5.00 Low Stock Price Target$3.00 Potential Upside/Downside+619.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.13 million Net Margins-114.50% Pretax Margin-125.51% Return on Equity-73.74% Return on Assets-42.68% Debt Debt-to-Equity Ratio0.36 Current Ratio1.01 Quick Ratio0.85 Sales & Book Value Annual Sales$24.00 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.60Miscellaneous Outstanding Shares45,765,000Free Float28,940,000Market Cap$25.45 million OptionableNot Optionable Beta-0.05 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:IPA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.